← Back to Search

Selective Serotonin Reuptake Inhibitor

Escitalopram for Agitation in Alzheimer's Disease (S-CitAD Trial)

Phase 3
Waitlist Available
Research Sponsored by JHSPH Center for Clinical Trials
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Alzheimer's dementia diagnosed clinically by the National Institute on Aging (NIA) and the Alzheimer's Association (AA) (2011 NIA/AA criteria)
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up after 12 weeks
Awards & highlights

S-CitAD Trial Summary

This trial will test whether the antidepressant escitalopram is effective and safe for treating agitation in Alzheimer's dementia.

Who is the study for?
This trial is for individuals with Alzheimer's dementia experiencing frequent and severe agitation/aggression. Participants must be diagnosed by NIA/AA criteria, have a caregiver, and if using antipsychotics, the dosage should be stable. Excluded are those with major depression recently, residing in certain care facilities, recent medication changes that affect the brain or heart function issues.Check my eligibility
What is being tested?
The study tests escitalopram's safety and effectiveness against placebo for reducing agitation in Alzheimer's patients. Participants will either receive escitalopram or a placebo to compare outcomes between the two groups.See study design
What are the potential side effects?
Escitalopram may cause side effects like nausea, sleep disturbances, fatigue, dry mouth, increased sweating and could potentially worsen some psychiatric conditions such as depression.

S-CitAD Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with Alzheimer's dementia.

S-CitAD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~after 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and after 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
modified- Alzheimer's Disease Cooperative Study--Clinical Global Impression of Change (mADCS-CGIC)

Side effects data

From 2019 Phase 4 trial • 115 Patients • NCT01902004
23%
Sleepiness/Sedation
10%
Headache
8%
Tension/Inner Unrest
8%
Reduced Salivation
8%
Concentration Difficulties
8%
Diminished Sexual Drive
6%
Asthenia/Lassitude/Increased Fatigability
6%
Constipation
6%
Polyuria/Polydipsia
6%
Orthostatic Dizziness
4%
Nausea/Vomiting
4%
Erectile Dysfunction
4%
Failing Memory
2%
Diarrhea
2%
Increased Duration of Sleep
2%
Reduced Duration of Sleep
2%
Increased Dream Activity
2%
Accomodation Disturbance
2%
Increased Tendancy to Sweating
2%
Weight Gain
2%
Ejaculatory Dysfunction
2%
Micturtion Disturbances
100%
80%
60%
40%
20%
0%
Study treatment Arm
Escitalopram and Placebo
Escitalopram and Memantine

S-CitAD Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: EscitalopramExperimental Treatment1 Intervention
Escitalopram up to 15mg/day taken as 1-3 capsules each containing 5mg escitalopram once per day in the morning
Group II: PlaceboPlacebo Group1 Intervention
1-3 capsules each containing placebo only once per day in the morning
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Escitalopram
FDA approved

Find a Location

Who is running the clinical trial?

National Institute on Aging (NIA)NIH
1,676 Previous Clinical Trials
28,021,312 Total Patients Enrolled
269 Trials studying Dementia
23,628,041 Patients Enrolled for Dementia
JHSPH Center for Clinical TrialsLead Sponsor
12 Previous Clinical Trials
10,165 Total Patients Enrolled
1 Trials studying Dementia
50 Patients Enrolled for Dementia
Constantine Lyketsos, MD, MHSStudy ChairJohns Hopkins University
2 Previous Clinical Trials
1,836 Total Patients Enrolled
1 Trials studying Dementia
1,650 Patients Enrolled for Dementia

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Escitalopram for Agitation in Alzheimer's Disease
Dave Shade 2018. "Escitalopram for Agitation in Alzheimer's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03108846.
All > Alzheimers Disease Ventura > Paid Studies Arkansas
~26 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top